scholarly journals Factors Associated with Hepatitis B Surface Antigen Seroprevalence amongst Pregnant Women in Kenya

2018 ◽  
Vol 08 (05) ◽  
pp. 456-467
Author(s):  
Z. Gatheru ◽  
F. Murila ◽  
J. Mbuthia ◽  
F. Okoth ◽  
F. Kanyingi ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Pregnant Women ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Factors Associated

scholarly journals Hepatitis B vaccination coverage and risk factors associated with incomplete vaccination of children born to hepatitis B surface antigen-positive mothers, Denmark, 2006 to 2010

2016 ◽  
Vol 21 (7) ◽  
Author(s):  
Asja Kunoee ◽  
Jens Nielsen ◽  
Susan Cowan
Keyword(s):  
Risk Factors ◽  
Hepatitis B ◽  
Pregnant Women ◽  
Surface Antigen ◽  
Vaccination Coverage ◽  
Universal Screening ◽  
Hepatitis B Surface Antigen ◽  
Hepatitis B Vaccination ◽  
Factors Associated ◽  
Chronic Hbv

In Denmark, universal screening of pregnant women for hepatitis B has been in place since November 2005, with the first two years as a trial period with enhanced surveillance. It is unknown what the change to universal screening without enhanced surveillance has meant for vaccination coverage among children born to hepatitis B surface antigen (HBsAg)-positive mothers and what risk factors exist for incomplete vaccination. This retrospective cohort study included 699 children of mothers positive for HBsAg. Information on vaccination and risk factors was collected from central registers. In total, 93% (651/699) of the children were vaccinated within 48 hours of birth, with considerable variation between birthplaces. Only 64% (306/475) of the children had received all four vaccinations through their general practitioner (GP) at the age of two years, and 10% (47/475) of the children had received no hepatitis B vaccinations at all. Enhanced surveillance was correlated positively with coverage of birth vaccination but not with coverage at the GP. No or few prenatal examinations were a risk factor for incomplete vaccination at the GP. Maternity wards and GPs are encouraged to revise their vaccination procedures and routines for pregnant women, mothers with chronic HBV infection and their children.

Hepatitis B Surface Antigen Prevalence Among Pregnant Women in Urban Areas: Implications for Testing, Reporting, and Preventing Perinatal Transmission

PEDIATRICS ◽  
2003 ◽  
Vol 111 (Supplement_1) ◽  
pp. 1192-1197 ◽  
Author(s):  
Gary L. Euler ◽  
Karen G. Wooten ◽  
Andrew L. Baughman ◽  
Walter W. Williams
Keyword(s):  
Hepatitis B ◽  
Prenatal Care ◽  
Pregnant Women ◽  
Urban Area ◽  
Surface Antigen ◽  
Urban Areas ◽  
Hepatitis B Surface Antigen ◽  
Prevalence Rates ◽  
Odds Ratios ◽  
Factors Associated

Objectives. To estimate race/ethnicity-specific prevalence of hepatitis B surface antigen (HBsAg) in pregnant urban women and to evaluate factors associated with maternal HBsAg testing. Methods. A multicenter, retrospective chart review was conducted of a racially/ethnically stratified random sample of maternal/infant charts of 10 523 women who gave birth to live infants during 1990–1993 in 4 urban areas in the United States. Data were collected on multiple variables, including demographic variables, HBsAg test dates and results, prenatal care type, and amount and source of payment. Results. HBsAg prevalence among white non-Hispanics was 0.60% (95% confidence interval [CI]: 0.22–0.98), black non-Hispanics 0.97% (95% CI: 0.48–1.47), Hispanics 0.14% (95% CI: 0.01–0.26), and Asians 5.79% (95% CI: 4.42–7.16). HBsAg testing rates increased from 56.6% in 1990 to 78.2% in 1993. Factors associated with not being tested varied by urban area, but in the combined area model, they were having no or private prenatal care (odds ratios: 18.75 and 5.07, respectively) and being black (odds ratios: 2.08). Only 20.9% (95% CI: 19.1%–22.8%) of those not tested prenatally were tested at delivery. The expected number of infants born to HBsAg-positive study-area women was 3327 using study prevalence rates, compared with 1761 using national rates. Conclusions. To help ensure that all urban infants who are born to HBsAg-positive women receive appropriate prophylaxis, health officials in urban areas should use urban-area prevalence rates to ascertain completeness of reporting maternal HBsAg positivity. Needed steps to increase maternal HBsAg testing rates include ensuring that more pregnant women receive prenatal care, promoting testing by private providers, educating providers about testing in all racial and ethnic groups, and reminding providers to test at delivery those women not tested prenatally.

scholarly journals Seroprevalence of hepatitis B surface antigen and associated risk factors among pregnant women

2018 ◽  
Vol 12 (10) ◽  
pp. 904-909 ◽  
Author(s):  
Sirin Cetin ◽  
Meryem Cetin ◽  
Ebru Turhan ◽  
Kenan Dolapcioglu
Keyword(s):  
Public Health ◽  
Risk Factors ◽  
Hepatitis B ◽  
Pregnant Women ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Multivariate Logistic Regression Analysis ◽  
Hbv Infection ◽  
Factors Associated ◽  
History Of

Introduction: Hepatitis B infection is a serious global public health problem. The aim of the study was to assess the seroprevalance of hepatitis B surface antigen (HBsAg), as well as the risk factors associated with hepatitis B virus (HBV) infection among pregnant women attending antenatal care clinics of the University Hospital in Antioch, Turkey. Methodology: This descriptive cross-sectional study was carried out between May 2016 and December 2016. The Chi-squared was utilized to estimate the statistical significance of the association between socio-demographic variables and HBsAg status. The results were generated as proportions odds ratio (OR) with their 95% confidence intervals (Cl) and calculated by using both univariate and multivariate logistic regression analysis. Results: The seroprevalence of HBsAg was found to be 2.1%. A significant association was observed between age and HBsAg seropositivity (p = 0.027). History of blood transfusion (AOR = 9.51, 95% CI = 1.92-46.80, p = 0.006), history of hepatitis (AOR = 11.13, 95% CI = 2.02-61.28, p = 0.006), tattooing (AOR = 13.64, 95% CI = 2.52-73.76, p = 0.002) and a history of household/close contact (AOR = 11.10, 95% CI = 1.56-78.65, p = 0.016) were significantly associated with the risk of HBV infection. Conclusions: Data regarding the seroprevalence of HBsAg and risk factors associated with HBV infection in pregnant women plays a crucial role in evaluating the effectiveness of the public health protection policies and the strategies to control the disease.

Discrepant Hepatitis B Surface Antigen Results in Pregnant Women Screened to Identify Hepatitis B Virus Infection

2014 ◽  
Vol 165 (4) ◽  
pp. 773-778 ◽  
Author(s):  
Steven L. Veselsky ◽  
Tanja Y. Walker ◽  
Nancy Fenlon ◽  
Chong-Gee Teo ◽  
Trudy V. Murphy
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Pregnant Women ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Hepatitis B Virus Infection ◽  
B Virus

Prevention of Hepatitis B Infection in Newborns Through Mass Screening and Delayed Vaccination of All Infants of Mothers With Hepatitis B Surface Antigen

PEDIATRICS ◽  
1989 ◽  
Vol 83 (6) ◽  
pp. 1041-1048
Author(s):  
Solko W. Schalm ◽  
J. Adriaan Mazel ◽  
Gijsbert C. de Gast ◽  
Rudolf A. Heijtink ◽  
Meindert J. Botman ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Pregnant Women ◽  
Rural Area ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Large City ◽  
Hepatitis B Infection ◽  
Active Vaccination ◽  
Group A ◽  
Group B

Beginning in 1982 all pregnant women undergoing prenatal routine blood analysis in three large city hospitals and one large rural area were tested for hepatitis B surface antigen (HBsAg). Infants of all HBsAg-positive mothers received hepatitis B immunoglobulin (HBIg), 0.5 mL/kg of body weight within two hours of birth and, after randomization, 10 µg of hepatitis B vaccine either at 0, 1, 2, and 11 months of age (schedule A) or at 3, 4, 5, and 11 months of age (schedule B). A second injection of HBIg (1 mL) was given to infants on schedule B at 3 months of age. Blood samples were obtained at 3, 6, 11, 12, 24, and 36 months. In a two-year period, 28,412 pregnant women were tested for HBsAg; screening efficiency varied between 85% and 98%. The overall prevalence of HBsAg was 0.8%, with a marked variation between urban centers (2.2%) and the rural area (0.3%). Vaccinations were received by 180 of 193 infants of HBsAg-positive mothers (90 on schedule A and 90 on schedule B). Concentrations of hepatitis B surface antibody less than 10 IU/L were observed in nine instances in five children from group A and in seven instances in six children from group B. Four hepatitis B viral infections (two HBsAg carriers, two who underwent antihepatitis B core seroconversions) were recorded in group A v one infection (antihepatitis B core seroconversion) in group B. The protective efficacy of the program (screening plus passive immunization and delayed vaccination) was 94%. The estimated cost of preventing one case of hepatitis B infection in neonates was $3,000 (US currency). It is concluded that screening all pregnant women for HBsAg can be introduced effectively at reasonable costs in a country with a low prevalence of HBsAg and a high proportion of home deliveries. Delayed active vaccination starting at 3 months of age may be an effective and, for reasons of high compliance and low cost, attractive alternative to early active vaccination.

Kinetics of Hepatitis B Surface Antigen in Pregnant Women with and without Tenofovir Disoproxil Fumarate

2021 ◽  
Author(s):  
Huai‐Lung Chang ◽  
Wan‐Hsin Wen ◽  
Chien‐Nan Lee ◽  
Yu‐En Chiu ◽  
Chun‐Jen Liu ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Pregnant Women ◽  
Surface Antigen ◽  
Tenofovir Disoproxil Fumarate ◽  
Hepatitis B Surface Antigen ◽  
Kinetics Of
Sign in / Sign up

Export Citation Format

Share Document